Treating anaemia in patients with chronic kidney disease : what evidence for using ESAs, after a 30-year journey?

Copyright by Società Italiana di Nefrologia SIN, Rome, Italy..

Erythropoiesis Stimulating Agents (ESAs) are well-tolerated and effective drugs for the treatment of anaemia in patients with chronic kidney disease. In the past, scientific research and clinical practice around ESAs have mainly focused on the haemoglobin target to reach, and to moving towards the normality range; more cautious approach has been taken more recently. However, little attention has been paid to possible differences among ESA molecules. Although they present a common mechanism of action on the erythropoietin receptor, their peculiar pharmacodynamic characteristics could give different signals of activation of the receptor, with possible clinical differences. Some studies and metanalyses did not show significant differences among ESAs. More recently, an observational study of the Japanese Registry of dialysis showed a 20% higher risk of mortality from any cause in the patients treated with long-acting ESAs in comparison to those treated with short-acting ESAs; the difference increased in those treated with higher doses. These results were not confirmed by a recent, post-registration, randomised, clinical trial, which did not show any significant difference in the risk of death from any cause or cardiovascular events between short-acting ESAs and darbepoetin alfa or methoxy polyethylene glycol-epoetin beta. Finally, data from an Italian observational study, which was carried out in non-dialysis CKD patients, showed an association between the use of high doses of ESA and an increased risk of terminal CKD, limited only to the use of short-acting ESAs. In conclusion, one randomised clinical trial supports a similar safety profile for long- versus short-acting ESAs. Observational studies should always be considered with some caution: they are hypothesis generating, but they may suffer from bias by indication.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:37

Enthalten in:

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia - 37(2020), 4 vom: 11. Aug.

Sprache:

Italienisch

Beteiligte Personen:

Locatelli, Francesco [VerfasserIn]
Del Vecchio, Lucia [VerfasserIn]
De Nicola, Luca [VerfasserIn]
Minutolo, Roberto [VerfasserIn]

Themen:

Anaemia
Chronic kidney disease
ESAs
Erythropoiesis stimulating agents
Hematinics
Journal Article
Long acting ESAs
Mortality
Review
Short acting ESAs

Anmerkungen:

Date Completed 05.08.2021

Date Revised 05.08.2021

published: Electronic

Citation Status MEDLINE

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM313837988